Ultra rapid formulation insulin lispro - Eli Lilly and Company
Alternative Names: insulin lispro-aabc injection; Liumjev™; LY-900014; Lyumjev; Lyumjev U-100; Lyumjev U-200; rapid acting insulin - Eli Lilly and Company; Ultra rapid lispro; URLiLatest Information Update: 15 Nov 2022
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 19 Sep 2022 Additional safety and efficacy data from the phase III PRONTO-Peds trial in Type 1 diabetes presented at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD- 2022)
- 03 Jun 2022 Safety and efficacy data from the phase III PRONTO-Peds trial in Type 1 diabetes mellitus presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)
- 04 Feb 2022 Eli Lilly and Company completes the PRONTO-Time in Range phase III trial for Type 2 diabetes mellitus (Combination therapy) in USA and Puerto Rico (NCT04605991)